Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

The Lundquist Institute

Neither a doctor nor a teaching hospital

Research payments

$1,744,504

197 payments

Through program year 2025, The Lundquist Institute is reported as receiving $1,744,504 in research payments, across 197 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $509,531 61
2024 Research $383,157 34
2023 Research $349,201 35
2022 Research $180,650 35
2021 Research $279,786 27
2020 Research $31,180 4
2019 Research $11,000 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Instylla Inc. $457,669 32 payments
  2. Pfizer Inc. $361,902 26 payments
  3. Ascendis Pharma, Inc. $360,585 36 payments
  4. Regeneron Pharmaceuticals, Inc. $260,902 50 payments
  5. Merck Sharp & Dohme Corporation $100,822 3 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $86,960 12 payments
  7. Zimmer Biomet Holdings, Inc. $71,319 20 payments
  8. Amryt Pharma Holdings Ltd $15,240 6 payments
  9. Sanofi US Services Inc. $11,088 9 payments
  10. GlaxoSmithKline, LLC. $11,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Prospective, Non-Randomized Single-Arm Pilot Study to Assess the Safety and Effectiveness of Instylla HES For Transcatheter Embolization of Arterial Bleeds. $448,244 29 payments
  2. foresiGHt $206,456 18 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $172,671 27 payments
  4. foresiGHt extension $154,129 18 payments
  5. A Randomized Doubleblind Phase 3 Study of Tucatinib Or Placebo in Combination With Trastuzumab and Pertuzumab As Maintenance Therapy for Metastatic Her2 Breast Cancer Her2climb05 $151,902 21 payments
  6. Impact of Low LDLC Obesity and Their Interaction on Coronary Atherosclerosis and Cardiovascular Risk in Rheumatoid Arthritis $150,000 3 payments
  7. A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $88,230 23 payments
  8. Multidisciplinary Approach to Patient Physician Partnership in Treating to Target in Rheumatoid Arthritis Mappitra $50,000 1 payment
  9. PoCP study in FSGS $46,801 2 payments
  10. A Phase 2 Study of Pembrolizumab MK-3475 every 6 weeks Q6W in Participants with Relapsed or Refractory Classical Hodgkin s Lymphoma rrcHL or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma rrPMBCL $45,795 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record